Multilevel Determinants of HIV Pre-Exposure Prophylaxis (Prep) Utilization and Health Disparities among Black and Hispanic Women

Project Director: Jamie Simmons

The use of antiretroviral medication—brand name Truvada—for the prevention of HIV (pre-exposure prophylaxis; PrEP) among Black and Latina women in the U.S. has the potential to significantly reduce disproportionately high rates of HIV in these groups. However, adoption of PrEP by women of color has been very limited, thereby reducing the public health benefit of PrEP to address racial and ethnic disparities in HIV transmission among women. The proposed study is designed to provide a knowledge base regarding key obstacles and facilitators of PrEP utilization that can be applied to develop effective PrEP interventions and delivery models for Black and Latina women.

For more information: Abstract

  • About NDRI
          Since 1967, National Development and Research Institutes, Inc. (NDRI), a private, not-for-profit 501(c)(3) organization, has conducted substance use and other bio-behavioral research nationwide and throughout the world.

          Drawing on the expertise of our interdisciplinary professional staff and our partners such as medical centers, treatment and prevention programs, universities, CBOs, industry and government NDRI has advanced public health across diverse populations including high-risk and underserved persons, uniformed services, youth and veterans.

          In addition to its focus on addiction, NDRI, organized under specialized institutes, has generated scientific discoveries associated with infectious diseases (particularly HIV and Hepatitis C), overdose, chronic pain, prevention of cardiovascular disease and cancer, tobacco control and criminal justice.


    Follow Us on Facebook